OpenLobby.EU
Explore

EU cooperation on Health Technology Assessment

Food safety, Public health

Links

Public consultation

ID: 1565

Lobbying Activity

6 responses

Consultation response

Bureau Européen des Unions de Consommateurs, 28 Mar 2018

BEUC comments to European Commission’s proposal Regulation Health Technology Assessment The European Consumers Organization (BEUC) welcomes the European Commission’s proposal on Health Technology Assessment (HTA). Too many new drugs or medical devices do not make a real difference compared to…

Consultation response

European Federation of Pharmaceutical Industries and Associations, 30 Mar 2018

EFPIA welcomes the Commission’s proposal for a Regulation on HTA. This proposal presents a unique opportunity to ensure a degree of harmonisation throughout the European Union, thereby leading to faster patient access to new innovative medicines and synergies in clinical evidence generation needs…

Consultation response

Johnson Johnson, 29 Mar 2018

Johnson & Johnson (JnJ) welcomes the opportunity to comment on the proposed HTA Regulation. Our companies provide innovative technologies across the Pharmaceutical, Medical Device and Diagnostic sectors, advancing the health and well-being of people around the world. A significant proportion of…

Consultation response

EUROPEAN ORGANISATION FOR RARE DISEASES, 30 Mar 2018

Transparency and Health Technology Assessment cooperation as proposed by the Regulation are the only real antidote to secrecy and political games Why EURORDIS supports the proposal for a Regulation on Health Technology Assessment (HTA) Cooperation in Europe 30 March 2018, Paris –…

Consultation response

European Coordination Committee of the Radiological, Electromedical and healthcare IT Industry, 30 Mar 2018

COCIR welcomes the EC proposal on HTA cooperation in the European Union, adopted on 31 January 2018, in which the majority of the concerns highlighted in COCIR contribution to the European Commission public consultation on strengthening of the EU cooperation on HTA are considered. COCIR believes…

Consultation response

Pharma Deutschland e.V, 26 Mar 2018

Arzneimittel-Hersteller können von einem einheitlichen europäischen HTA-Prozess profitieren, da die unterschiedlichen nationalen und regionalen Anforderungen die Unternehmen vor große Herausforderungen stellen. So variieren der Startzeitpunkt und die Dauer des HTA-Prozesses sowie die klinischen…